|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Kevin T. Conroy||Chairman, Pres & CEO||1,82M||845,39k||1966|
|Mr. Jeffrey T. Elliott CFA||Chief Financial Officer||701,77k||N/D||1978|
|Ms. Ana Hooker||Sr. VP of Operations||627,49k||N/D||1966|
|Mr. D. Scott Coward||Chief Admin. Officer, Sr. VP, Gen. Counsel & Sec.||741,87k||6,6M||1965|
|Mr. Jake Orville||Sr. VP of Pipeline||769,63k||N/D||1974|
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; and Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer. The company's pipeline products focuses on the research and development of enhancing Cologuard's performance characteristics, and blood or other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; Biocartis N.V.; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
L'ISS Governance QualityScore di Exact Sciences Corporation al 7 dicembre 2019 è 7. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 7; diritti degli azionisti: 8; retribuzione: 5.